Proliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Correlates with the Presence of Atherosclerosis Cardiovascular Disease

Lu Gao  
Beijing Tongren Hospital

Wei Zhao  
Beijing Tongren Hospital

Jin-Kui Yang  
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University

Ming-Zhao Qin (✉ qinmingzhao58@163.com)  
Beijing Tongren Hospital

Research

**Keywords:** Atherosclerosis cardiovascular disease (ASCVD), Type 2 diabetes mellitus (T2DM), Proliferative, Diabetic retinopathy (DR)

**DOI:** [https://doi.org/10.21203/rs.3.rs-196397/v1](https://doi.org/10.21203/rs.3.rs-196397/v1)

**License:** [©] This work is licensed under a Creative Commons Attribution 4.0 International License.  
[Read Full License](https://creativecommons.org/licenses/by/4.0/)

Preprints are preliminary reports that have not undergone peer review. They should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.
Abstract

Background: Atherosclerosis cardiovascular disease (ASCVD) is the main cause of morbidity and mortality in Type 2 diabetes mellitus (T2DM). As most diabetic patients with ASCVD are asymptomatic, it is most neglected in clinical practice. For this reason, identifying high-risk ASCVD population with intensified treatment is very important. In recent years, the relationship between diabetic retinopathy (DR) and ASCVD has caused much academic concern, but the results are inconsistent. Moreover, whether all grades of DR increase the risk of ASCVD remains controversial. Most importantly, very few data can be found in China.

Objective: Our aim is to discuss whether all grades of DR increase the risk of ASCVD after adjustment for the traditional cardiovascular risk factors and to assess the independent contribution of DR to cardiovascular events in patients with T2DM, hoping to provide more evidence for early identification of ASCVD.

Research design and methods: A total of 425 T2DM patients with complete physical and biochemical data were included in the study. The grade of DR was assessed with two 45°color digital retinal images. Based on the presence of history of ASCVD, 425 T2DM patients were divided into 2 groups: ASCVD group and non-ASCVD group.

Results: Patients with ASCVD had a significantly higher level of age, fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) and higher proportion of history of ASCVD, female sex and lower level of alcohol, calculated glomerular filtration rate (eGFR) than non-ASCVD patients. Their trend to develop DR with ASCVD was significantly higher than patients with non-ASCVD ($\chi^2 = 5.805$, $P = 0.016$). DR was an independent statistical indicator of the presence of ASCVD [odds ratio (OR) (95% CI): 2.321 (1.152-4.678), $P = 0.018$]. Furthermore, when DR was divided into non-proliferative retinopathy (NPDR) and proliferative retinopathy (PDR) according to its severity, only PDR was significantly associated with incident ASCVD [OR (95% CI): 8.333 (1.813-38.304), $P = 0.006$]. After adjusting for traditional ASCVD risk factors, such an association still existed [OR (95% CI): 7.466 (1.355-41.137), $P = 0.021$].

Conclusion: DR associates strongly with ASCVD in the Chinese population with T2DM. With the severity of DR increasing, the risk of ASCVD also grows. After adjustment for traditional risk factors, PDR is still an independent risk marker for ASCVD.

Introduction

Diabetic retinopathy (DR) is one of the most common and severe microvascular complications of diabetes mellitus (DM). According to the WHO study, the number of diabetic patients worldwide has reached 366 million in 2011, and by 2025, this figure is expected to jump to more than 500 million, and about one-third of them will develop DR (1). Increasing DR severity is associated with an increased risk of vision impairment or loss and risk of vision-threatening proliferative disease over time (2).
DM, defined by elevated glycemic markers, is a major risk factor for atherosclerosis cardiovascular disease (ASCVD), which is the most common cause of death among adults with diabetes mellitus (3), and thus is considered to have an ASCVD risk equivalent. ASCVD is the leading cause of mortality and morbidity among the DM population, accounting for 70% of all deaths (4) (5). However, persons with DM are at increased risk of silent myocardial ischemia and myocardial infarction (MI): up to one-third of patients with DM who experience an acute MI do not manifest chest pain (6). These patients often do not have timely and effective treatment in the event of emergency with high fatality rate. As a result, early recognition of such high-risk ASCVD population is very important.

The association between DR and ASCVD in patients with type 2 DM (T2DM) has attracted considerable attention, as traditional risk factors for ASCVD, such as hypertension, hyperlipidemia, duration of hyperglycemia and magnitude of glycemia control are well known risk factors for progression and development of DR (7). And, similar pathophysiological processes may be contributed in ASCVD and DR. Previous studies have reported the fact that DR presence increases the risk of ASCVD, such as stroke (8) (9) and coronary heart disease (CHD) (10) (11). However, some studies (12, 13) pointed out that this correlation is weakened after adjustment for traditional ASCVD risk factors. What remains disputed is whether each stage of DR is associated with increased risk of ASCVD. Furthermore, present studies focused mainly on European and American people, leading to limited data on Asian people, especially Chinese. The aim of this study is to discuss whether the presence or severity of DR is associated with ASCVD independent of traditional cardiovascular risk factors and to evaluate the independent effect of DR on cardiovascular events in patients with T2DM.

**Research Design And Methods**

**Study population**

The study participants were diagnosed DM patients from geriatric and endocrine ward in Beijing Tongren Hospital, chosen during January 2018 and June 2020. 447 received examinations including a physical examination, blood glucose and lipid measurements, renal function tests and ophthalmic examination. After excluding subjects with cataracts, glaucoma, age related retinopathy or other eye diseases, impaired renal function [calculated glomerular filtration rate (eGFR) <60 ml/min], cancer, chronic obstructive pulmonary disease (COPD), T1DM, secondary diabetes and chronic pancreatitis, 425 participants with T2DM were available for the follow-up test that divided them into two groups, 65 with ASCVD and 360 without.

**Data collection**

All participants received a standardized examination. Data regarding age, smoking, alcohol consumption, physical activity, educational level, and history of diabetes, hypertension and ASCVD were obtained with detailed medical records. Body Mass Index (BMI) was calculated as weight (kg) divided by height squared (m²). Waist circumference (WC) was measured at the level of the umbilicus in cm. Blood
pressure (BP) was measured 3 times when participants were seated, and the average of the last 2 measurements was adopted. Blood samples were collected after an overnight fast for the determination of plasma glucose, HbA1c, total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) concentrations and serum creatinine (Scr). GFR was estimated by using the modified MDRD formula for Chinese patients (14): eGFR (ml/min/1.73m$^2$) = 175 × Scr$^{-1.234}$ × age$^{-0.179}$ × 0.79 (if female).

**Definition of clinical and biochemical variables**

Various non-fatal ASCVD were determined according to a patient’s self-report. CHD can be defined with a history of myocardial infarction, at least one coronary stenosis more than 50% by coronary angiography or coronary CTA, a surgical history of revascularization (including percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)). The definition of stroke included a history of language or physical dysfunction continuing for more than 24 h and ischemic or hemorrhagic stroke diagnosed using imaging examination [computed tomography or magnetic resonance imaging]. ASCVD referred to a history of CHD or stroke, as defined above. Diagnosis of hypertension was based on meeting any of three criteria: systolic blood pressure (SBP) of ≥ 140 mmHg, diastolic blood pressure (DBP) of ≥ 90 mmHg or current use of antihypertensive drugs (15). Central obesity is based on WC cutoff ≥ 80 cm in women and ≥ 90 cm in men according to the IDF ethnicity-specific definitions for Asian (16). Overweight and obesity are respectively identified as BMI 24-28 kg/m$^2$ and BMI equal to or over 28 kg/m$^2$ according to the Working Group on Obesity in China (WGOC) (2002) (17). Smokers were defined as those who had smoked ≥ 1 cigarette/day for at least 1 year. Drinkers were defined as those who had consumed ≥ 30 g of alcohol/week on average for at least 1 year. Regular leisure-time physical activity was defined as participation in moderate or vigorous activity for 30 minutes or more per day at least 3 days a week. Educational level was also recorded and categorized into two groups: low (illiteracy, primary, and secondary education), and high (high school education, college or university education). The family history of ASCVD goes for first-degree relatives (biological mother, father, brothers, or sisters).

**Assessment of retinopathy**

All participants received eye examinations by an ophthalmologist and had a bilateral retinal photograph taken of the fundus through dilated pupils. Two 45u color digital images of the retina were taken of each eye by a technologist using a Topcon TRC-NW7SF fundus camera (Topcon, Tokyo, Japan), an ophthalmic digital imaging system. The first image was centered on the macula, and the second on the optic nerve. The photographs were graded by two qualified ophthalmologists from the Eye Center of Capital Medical University, Beijing Tongren Hospital according to the international clinical diabetic retinopathy severity scale (18): (i) no diabetic retinopathic changes (NDR); (ii) mild non-proliferative diabetic retinopathy (NPDR); (iii) moderate NPDR; (iv) severe NPDR; and (v) proliferative diabetic retinopathy (PDR). The degree of DR was determined according to the grading in the most affected eye. The ophthalmologists grading the photographs were blinded to the patients’ characteristics.
Statistical analysis

All statistical analyses were conducted with the software package SPSS version 22.0 for Windows. For the continuous variables with a normal distribution, mean±SD was reported and the independent t-test was used to compare subjects with no diabetic retinopathy (NDR) with any stage of diabetic retinopathy (DR). For the discrete variables or the continuous variables without a normal distribution, the median (P25–P75) was reported, and a Mann-Whitney rank test was used to examine the differences between the groups. In the meantime, distribution of discrete/qualitative variables was compared by Pearson chi-square test. Multivariable logistic regression analysis was used to estimate crude and adjusted odds ratios (ORs) (95% CIs) to allow for differences between groups with respect to demographic and risk factors and control for potentially confounding variables. A p-value of less than 0.05 was considered statistically significant.

Results

A total of 425 T2DM patients with (n=65) or without (n=360) ASCVD comprised the study groups, with 165 men and 260 women and average age of 58.72±6.82. The total prevalence of DR was 11.29%, 9.65% with NPDR and 1.64% with PDR respectively.

The demographic and biochemical parameters of the two groups are shown in Table 1. Compared with the non-ASCVD group, patients with ASCVD were older, with higher levels of FPG and HbA1c and higher proportion of female and family history of ASCVD, while their level of eGFR and proportion of alcohol are lower. At the same time, there were no statistical differences between the two groups in duration of diabetes, the proportion of smoking, high educational level, physical activity, central obesity, generalized obesity, hypertension and the levels of SBP, DBP, TC, TG, HDL-C, LDL-C (Table 1).

Of the 360 subjects without ASCVD, 35 (9.7%) had DR. However, 13 cases (20.0%) were registered in the ASCVD group of 65 subjects, showing that the trend to DR in ASCVD group was significantly higher than in non-ASCVD group (Pearson $\chi^2$ =5.805, P =0.016), as is illustrated in Fig 1A. Furthermore, when DR was divided into NPDR and PDR based on its severity, a higher proportion of subjects with NPDR (9, 13.8%) and PDR (4, 6.2%) were found in the ASCVD group than from non-ASCVD group [32 subjects (9.0%) with NPDR (Pearson $\chi^2$ =1.975, P =0.160) and 3 subjects (0.9%) with PDR (Pearson $\chi^2$ =10.368, P =0.001)], and the difference of prevalence of PDR in two groups was statistically significant (Fig 1B).

Logistic regression analysis was performed to identify the risk factors of ASCVD. Age [odds ratio (OR) (95% CI): 1.814 (1.257-2.616), P =0.001], female sex [OR (95% CI): 1.971 (1.091-3.562), P =0.025], family history of ASCVD [OR (95% CI): 1.850 (1.085-3.155), P =0.024] and HbA1c [OR (95% CI): 1.198 (1.050-1.368), P =0.007] were relative risk factors and alcohol [OR (95% CI): 0.440 (0.222-0.872), P =0.019], eGFR [OR (95% CI): 0.990 (0.827-0.980), P =0.015] was relative protection factors of ASCVD (Table 2). Next, we found that DR [OR (95% CI): 2.321 (1.152-4.678), P =0.018] was significantly associated with ASCVD, and such a link was only true for PDR [OR (95% CI): 8.333 (1.813-38.304), P =0.006] when DR was divided into
NPDR and PDR. With an adjustment for age, sex, family history of ASCVD and duration of DM, PDR was significantly associated with and an independent risk factor for ASCVD [OR (95% CI): 9.430 (1.963-45.299), P =0.005]. Moreover, the association was not affected by an additional adjustment for smoking, alcohol, educational level, physical activity, obesity (central or general obesity), history of hypertension, SBP, DBP, HbA1c, LDL-C and eGFR [OR (95% CI): 7.466 (1.355-41.137), P =0.021] (Fig 2).

Discussion

In this study, the prevalence of ASCVD was 15.29% in T2DM patients. Age, female sex, the family history of ASCVD and hyperglycemia were risk factors of ASCVD, similar to previous research results. Coexisting diseases with T2DM, such as hypertension and hyperlipidemia are defined ASCVD risk factors, while DM itself is considered to have a CAD risk equivalent. ASCVD is the main cause of morbidity and mortality in diabetic patients, accounting for the biggest burden of DM directly or indirectly. The 2007-2008 China National Diabetes and Metabolic Disorders Study reported that the defined total of ASCVD prevalence was 1.44%, including 0.83% of stroke and 0.63% of CHD in Chinese adults over 20 years of age (19). The Da Qing impaired glucose tolerance (IGT) and Diabetes Study found the leading cause of death for patients with diabetes is ASCVD after 23-year follow-up (20).

It is very important for ASCVD to be detected and intervened timely. Due to the fact that the sensory nerve becomes insensitive and even lost in patients with diabetes, symptoms of ASCVD become asymptomatic or atypical. A variety of cardiovascular risk assessment tools having been proposed to assess the risk of developing ASCVD are available, such as Framingham risk score (FRS), Adult Treatment Panel III (ATP-III), EUROT - the Systematic Coronary Risk Evaluation (SCORE), Reynolds risk score (RRS), QRISK2 and the Chinese ten-year appraisal method for ischemic cardiovascular disease (ICVD), etc. But the suitability of these screening assessment tools are limited because the ethnic, region, environment, and the way of life of patients are different. Moreover, computed tomography (CT) and angiography can detect the evidence of stenosis or occlusion of vessels directly, but these clinical application can result in radiation exposure and sometimes unnecessary invasive diagnosis and treatment. Therefore, it’s necessary to look for a kind of both simple and non-invasive methods to identify ASCVD early in clinical.

In spite of growing controversy more evidence shows that microvascular diseases in T2DM has a predictive value on developing ASCVD. Micro- and macrovascular complications of T2DM have a “common soil”. Since the Framingham Heart Study and the Framingham Eye Study had reported the association between DR and the occurrence of cardiovascular events, people gradually realized the importance of DR beyond visual damage. The Atherosclerosis Risk in Communities (ARIC) study also found that DR was associated with an increased risk of ischemic stroke [hazard ratio (HR), 2.34; 95% confidence interval (CI), 1.13 to 4.86] over an average follow-up of 7.8 years in the middle-aged persons with diabetes, independent of other risk factors (8). Another ARIC study (21) showed that after controlling for traditional cardiovascular risk factors, participants with retinopathy had more than 2.5-fold higher risk of developing heart failure (HF) than those without retinopathy (HR 2.71; 95% CI 1.46 to 5.05). This association remained significant after further adjustments for glycemic control, carotid atherosclerosis,
and serum markers of endothelial dysfunction (HR 2.20, 95% CI 1.08 to 4.47). Recently, a meta-analysis showed that DR was significantly associated with increased risk of stroke [risk ratio (RR), 1.74; 95% CI 1.35 to 2.24], compared with patients without DR. Furthermore, DR was associated with a marginal increased risk of HF in patients with DM (RR 2.24; 95% CI 0.98 to 5.14) (9). Retinopathy proved to be an independent risk marker for CVD in patients with T2DM (22).

However, there is limited knowledge regarding whether this association is observed consistently in Asian populations, especially in Chinese. There exist differences in the epidemiologic and risk associations of ASCVD between white and Asian populations. There is a potential need for an ethnicity-specific risk model of ASCVD. Furthermore, what remains disputed is whether each stage of DR is associated with increased risk of ASCVD. A report from Finland showed that during the 7-year follow-up, only in patients with PDR at baseline, the risk of CHD events was statistically significantly higher compared with patients without DR (OR 2.31, 95% CI 1.21 to 4.40) (23). However, the Japan Diabetes Complications Study (JDCS) (24), comprised 2,033 patients with T2DM, confirmed that the presence of DR was found consistently to be associated with an increased risk of stroke and CHD after 8 years of follow-up, and further elucidated that even mild to moderate NPDR had a higher risk of CHD (HR 1.69; 95% CI 1.17-2.97) and stroke (HR 2.69; 95% CI 1.03-4.86) after adjusting for traditional cardiovascular risk factors. In our research, those T2DM patients with an eGFR <60 ml/min/1.73m\(^2\) were excluded specifically to avoid the confounding factor of renal insufficiency, which was associated with an increased risk of atherosclerosis. We found that the presence of DR was significantly associated with an increased risk of ASCVD in Chinese with T2DM. Furthermore, the incidence of ASCVD increased along with the severity of DR. After adjustment for age, sex and other traditional risk factors, PDR rather than NPDR was significantly associated with and an independent risk factor for ASCVD. In the presence of PDR, risk of ASCVD was 7-fold in T2DM patients and PDR offered risk information beyond that provided by those established risk factors.

DR is closely related with ASCVD in epidemiology, similar pathophysiologic processes may be also contributed in DR and diabetes-accelerated atherosclerosis. First, traditional risk factors for ASCVD, such as hypertension, hyperlipidemia, duration of hyperglycemia, magnitude of glycemic control and metabolic syndrome (MetS) are well known risk factors for progression and development of DR (7, 25). Secondly, neovascularization (retinal angiogenesis) is a key hallmark of PDR, and angiogenesis is also a common feature observed in advanced atherosclerotic lesions (26, 27). Early pathological changes of macro- and microvascular have similarities, perhaps microcirculation change can accelerate the progress of macrovascular lesions. In addition, more and more evidence support a major role for the unifying mechanism in the pathogenesis of diabetic macrovascular, as well as microvascular, complications (28). These mechanisms what are hexosamine pathway, activation of protein kinase C, oxidative stress, pathological effects of the renin-angiotensin-aldosterone system (RAAS), advanced glycation end product (AGE) formation, inflammation and modification of circulating macromolecules, etc, not only influence the development of DR, also affect the progress of atherosclerosis (29).
Our study has several limitations that must be taken into account. First of all, it may have unpredictable selection bias. Secondly, ASCVD patients in this article are confirmed cases by hospital, so that some potential ASCVD patients may be missed. This might lead to an underestimation of the prevalence of ASCVD in T2DM patients. Thirdly, as these associations are cross-sectional, the study design is incapable of estimating causal relation directly; therefore, our findings may suggest that PDR is an indicator, but not predictor of ASCVD. The adverse effects of DR on ASCVD in Chinese population should be confirmed further in a larger cohort study with a broader spectrum of potential confounding factors. However, we have no reasons to believe these would substantially bias the associations reported herein.

In conclusion, all our data confirm that DR associates strongly with ASCVD in the Chinese population with T2DM. With the severity of DR increasing, the risk of ASCVD also increases. After adjustment for traditional risk factors, PDR is an independent risk marker for ASCVD. Retinal blood vessel is the only microvascular which can be directly observed, it would certainly be exciting to assess whether the retinal microvasculature can be used as a ‘window’ into the state of the cardiovascular complications in patients with diabetes. DR is not only one of the most common microvascular complications of diabetes, but also a “warning sign” for ASCVD. Based on this research findings, we hope that clinicians should pay more attention to systemic vascular risk of the patients with DR, especially PDR, and suggest to incorporate PDR to clinical cardiovascular risk stratification in patients with diabetes.

**Abbreviations**

ASCVD: atherosclerosis cardiovascular disease; DR: diabetic retinopathy; NDR: no DR; NPDR: non-proliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; DM: diabetes mellitus; BMI: body mass index; WC: Waist circumference; FPG: fasting plasma glucose; HbA1c: glycated haemoglobin; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein; LDL-C: low-density lipoprotein cholesterol; eGFR: calculated glomerular filtration rate; OR: odds ratio; CI: confidence interval.

**Declarations**

**Acknowledgments**

Not applicable.

**Authors’ Contributions**

LG designed the experiments, collected and analyzed the data before writing the manuscript. WZ did the experiments, and was a contributor in collecting data. JKY and MZQ also helped design the study and revise the manuscript. All authors read and approved the final manuscript.

**Funding**
There is no funding for this study.

**Availability of data and materials**

The data used to support the findings of this study are available from the corresponding author upon request.

**Ethics approval and consent to participate**

The study was conducted with the approval from the Ethics Committee of Beijing Tongren Hospital, Capital Medical University, and adhered to the tenets of the Declaration of Helsinki. Written consent was obtained from each participant.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Chen XD, Gardner TW. A critical review: Psychophysical assessments of diabetic retinopathy. Survey of ophthalmology. 2020. doi: 10.1016/j.survophthal.2020.08.003.

2. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes care. 2012;35(3):556-64. doi: 10.2337/dc11-1909.

3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):143-52. doi: 10.1161/CIR.0b013e318282ab8f.

4. Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. The American journal of cardiology. 2005;96(3):363-5. doi: 10.1016/j.amjcard.2005.03.076.

5. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. The Canadian journal of cardiology. 2018;34(5):575-84. doi: 10.1016/j.cjca.2017.12.005.

6. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clinic proceedings. 2009;84(8):741-57. doi: 10.1016/s0025-6196(11)60525-9.

7. Pradeepa R, Surendar J, Indulekha K, Chella S, Anjana RM, Mohan V. Relationship of diabetic retinopathy with coronary artery disease in Asian Indians with type 2 diabetes: the Chennai Urban
8. Cheung N, Rogers S, Couper DJ, Klein R, Sharrett AR, Wong TY. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke; a journal of cerebral circulation. 2007;38(2):398-401. doi: 10.1161/01.str.0000254547.91276.50.

9. Zhu XR, Zhang YP, Bai L, Zhang XL, Zhou JB, Yang JK. Prediction of risk of diabetic retinopathy for all-cause mortality, stroke and heart failure: Evidence from epidemiological observational studies. Medicine. 2017;96(3):e5894. doi: 10.1097/md.0000000000005894.

10. Um T, Lee DH, Kang JW, Kim EY, Yoon YH. The Degree of Diabetic Retinopathy in Patients with Type 2 Diabetes Correlates with the Presence and Severity of Coronary Heart Disease. Journal of Korean medical science. 2016;31(8):1292-9. doi: 10.3346/jkms.2016.31.8.1292.

11. Targher G, Bertolini L, Zenari L, Lippi G, Pichiri I, Zoppini G, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabetic medicine: a journal of the British Diabetic Association. 2008;25(1):45-50. doi: 10.1111/j.1464-5491.2007.02327.x.

12. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes care. 2007;30(2):292-9. doi: 10.2337/dc06-1747.

13. Targher G, Bertolini L, Tessari R, Zenari L, Arcaro G. Retinopathy predicts future cardiovascular events among type 2 diabetic patients: The Valpolicella Heart Diabetes Study. Diabetes care. 2006;29(5):1178. doi: 10.2337/diacare.2951178.

14. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. Journal of the American Society of Nephrology: JASN. 2006;17(10):2937-44. doi: 10.1681/asn.2006040368.

15. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507-20. doi: 10.1001/jama.2013.284427.

16. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5. doi: 10.1161/circulationaha.109.192644.

17. Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomedical and environmental sciences: BES. 2002;15(1):83-96.

18. Wilkinson CP, Ferris FL, 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology.
2003;110(9):1677-82. doi: 10.1016/s0161-6420(03)00475-5.

19. Yang ZJ, Liu J, Ge JP, Chen L, Zhao ZG, Yang WY. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. European heart journal. 2012;33(2):213-20. doi: 10.1093/eurheartj/ehr205.

20. An Y, Zhang P, Wang J, Gong Q, Gregg EW, Yang W, et al. Cardiovascular and All-Cause Mortality Over a 23-Year Period Among Chinese With Newly Diagnosed Diabetes in the Da Qing IGT and Diabetes Study. Diabetes care. 2015;38(7):1365-71. doi: 10.2337/dc14-2498.

21. Cheung N, Wang JJ, Rogers SL, Brancati F, Klein R, Sharrett AR, et al. Diabetic retinopathy and risk of heart failure. Journal of the American College of Cardiology. 2008;51(16):1573-8. doi: 10.1016/j.jacc.2007.11.076.

22. Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. The American journal of cardiology. 2009;103(10):1364-7. doi: 10.1016/j.amjcard.2009.01.345.

23. Miettinen H, Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Retinopathy predicts coronary heart disease events in NIDDM patients. Diabetes care. 1996;19(12):1445-8. doi: 10.2337/diacare.19.12.1445.

24. Kawasaki R, Tanaka S, Tanaka S, Abe S, Sone H, Yokote K, et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. Ophthalmology. 2013;120(3):574-82. doi: 10.1016/j.opth.2012.08.029.

25. Gao L, Xin Z, Yuan MX, Cao X, Feng JP, Shi J, et al. High Prevalence of Diabetic Retinopathy in Diabetic Patients Concomitant with Metabolic Syndrome. PloS one. 2016;11(1):e0145293. doi: 10.1371/journal.pone.0145293.

26. Moreno PR, Purushothaman KR, Zias E, Sanz J, Fuster V. Neovascularization in human atherosclerosis. Current molecular medicine. 2006;6(5):457-77.

27. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Current diabetes reviews. 2006;2(1):71-98.

28. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-25.

29. Ellis TP, Choudhury RH, Kaul K, Chopra M, Kohner EM, Tarr JM, et al. Diabetic retinopathy and atherosclerosis: is there a link? Current diabetes reviews. 2013;9(2):146-60.

**Tables**

**Table 1** Clinical characteristic of studied subjects with and without ASCVD.
|                              | Total   | non-ASCVD | ASCVD   | P value |
|------------------------------|---------|-----------|---------|---------|
| Number (%)                   | 425     | 360 (84.71) | 65 (15.29) |         |
| Age (year)                   | 58.72±6.82 | 58.27±6.68 | 61.21±7.12 | 0.001   |
| Female (%)                   | 260 (61.2) | 212 (58.9) | 48 (73.8) | 0.023   |
| Smoking n (%)                | 112 (26.4) | 101 (28.1) | 11 (16.9) | 0.061   |
| Alcohol n (%)                | 125 (29.4) | 114 (31.7) | 11 (16.9) | 0.016   |
| High educational level n (%) | 26 (6.1)  | 22 (6.1)  | 4 (6.2)   | 0.989   |
| Physical activity n (%)      | 332 (78.1) | 281 (78.1) | 51 (78.5) | 0.942   |
| Family history of ASCVD n (%)| 187 (44.0) | 150 (41.7) | 37 (56.9) | 0.023   |
| Central obesity n (%)        | 311 (73.2) | 257 (71.4) | 54 (83.1) | 0.050   |
| General obesity              |         |           |          | 0.890   |
| Overweight n (%)             | 191 (44.9) | 162 (45.0) | 29 (44.6) |         |
| Obesity n (%)                | 132 (31.1) | 113 (31.4) | 19 (29.2) |         |
| Duration of DM (y)           | 10.39±3.24 | 10.34±3.16 | 10.69±3.70 | 0.416   |
| FPG (mmol/l)                 | 8.61±2.64 | 8.50±2.58 | 9.22±2.95 | 0.042   |
| HbA1c (%)                    | 7.36±1.75 | 7.25±1.68 | 7.94±2.04 | 0.004   |
| Hypertension n (%)           | 328 (77.2) | 275 (76.4) | 53 (81.5) | 0.363   |
| SBP (mmHg)                   | 150.56±20.17 | 150.30±20.20 | 152.06±20.11 | 0.518   |
| DBP (mmHg)                   | 87.16±11.19 | 87.37±11.25 | 85.98±10.86 | 0.360   |
| TC (mmol/l)                  | 5.37±1.14 | 5.37±1.13 | 5.37±1.19 | 0.977   |
| TG (mmol/l)                  | 2.31±1.96 | 2.33±2.05 | 2.19±1.36 | 0.588   |
| LDL-C (mmol/l)               | 2.71±0.54 | 2.71±0.53 | 2.73±0.59 | 0.802   |
| HDL-C (mmol/l)               | 1.45±0.29 | 1.45±0.29 | 1.47±0.32 | 0.589   |
| eGFR (ml/min/1.73m²)         | 92.42±17.68 | 93.31±17.73 | 87.53±16.69 | 0.015   |

Data are means±SE or raw numbers (%). Continuous data were used for univariate general linear models and categorical data were analyzed by χ² tests.

**Table 2** Odds ratios of metabolic factors for ASCVD.
|                                | B  | SE  | Wald | OR   | 95%CI            | P value |
|--------------------------------|----|-----|------|------|-----------------|---------|
| Age (per 10 years)             | 0.595 | 0.187 | 10.141 | 1.814 | 1.257-2.616     | 0.001   |
| Sex (f/m)                      | 0.679 | 0.302 | 5.053 | 1.971 | 1.091-3.562     | 0.025   |
| Smoking (y/n)                  | -0.649 | 0.351 | 3.423 | 0.522 | 0.263-1.039     | 0.064   |
| Alcohol (y/n)                  | -0.822 | 0.350 | 5.526 | 0.440 | 0.222-0.872     | 0.019   |
| High education (y/n)           | 0.007 | 0.561 | 0.000 | 1.007 | 0.335-3.026     | 0.989   |
| Physical activity (y/n)        | 0.024 | 0.327 | 0.005 | 1.024 | 0.539-1.946     | 0.942   |
| Family history of ASCVD (y/n)  | 0.615 | 0.272 | 5.103 | 1.850 | 1.085-3.155     | 0.024   |
| Central obesity (y/n)          | 0.677 | 0.351 | 3.723 | 1.967 | 0.989-3.913     | 0.054   |
| General obesity                |     |     |      |      |                 |         |
| Overweight (y/n)               | -0.111 | 0.334 | 0.110 | 0.895 | 0.466-1.721     | 0.740   |
| Obesity (y/n)                  | -0.174 | 0.363 | 0.228 | 0.841 | 0.412-1.714     | 0.633   |
| Duration of DM (y/n)           | 0.031 | 0.039 | 0.661 | 1.032 | 0.957-1.113     | 0.416   |
| FPG (per 1 mmol/l)             | 0.158 | 0.090 | 3.068 | 1.171 | 0.981-1.396     | 0.080   |
| HbA1c (per 1 %)                | 0.181 | 0.068 | 7.174 | 1.198 | 1.050-1.368     | 0.007   |
| Hypertension (y/n)             | 0.311 | 0.343 | 0.824 | 1.365 | 0.697-2.674     | 0.364   |
| SBP (per 10 mmHg)              | 0.051 | 0.066 | 0.597 | 1.052 | 0.925-1.197     | 0.440   |
| DBP (per 5 mmHg)               | -0.037 | 0.060 | 0.368 | 0.964 | 0.857-1.085     | 0.544   |
| TC (≥4.68 mmol/l)              | -0.080 | 0.302 | 0.071 | 0.923 | 0.510-1.668     | 0.790   |
| TG (≥1.70moll/l)               | -0.029 | 0.274 | 0.011 | 0.971 | 0.568-1.660     | 0.915   |
| Variable                                      | OR   | 95% CI          | p     |
|-----------------------------------------------|------|-----------------|-------|
| LDL-C (≥2.60 mmol/l)                         | 0.622| 0.362 - 2.959   | 1.864| 0.917 - 3.788 | 0.085 |
| HDL-C (m≤1.00 mmol/l; f≤1.30 mmol/l)          | 0.217| 0.323 - 0.453   | 1.243| 0.660 - 2.341 | 0.501 |
| eGFR (per 10 ml/min/1.73m²)                   | -0.105| 0.043 - 5.910 | 0.900 | 0.827 - 0.980 | 0.015 |

Binary univariate logistic regression was conducted to assess the association of ASCVD with different variables using the Entry method; odds ratios (ORs) and the 95% confidence intervals (CIs) given.